Mutations, dysregulation, and overexpression of protein kinases are involved in a multitude of disease processes. Around 1 in every 40 human genes codes for a protein kinase and nearly half of those genes map to either disease loci or cancer amplicons.

Tyrosine kinase enzymes (TKs) can be categorized into receptor tyrosine kinases (RTKs), non-receptor tyrosine kinases (NRTKs), and a small group of dual-specificity kinases (DSK) which can phosphorylate serine, threonine, and tyrosine residues. RTKs are transmembrane receptor that includes vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), insulin receptor (InsR) family, and the ErbB receptor family, which includes epidermal growth factor receptors (EGFR) and the human epidermal growth factor receptor-2 (HER2). NRTKs are cytoplasmic proteins that consist of nine families, including Abl, Ack, Csk, Fak, Fes/Fer, Jak, Src, Syk/Zap70, and Tec, with the addition of Brl/Sik, Rak/Frk, Rlk/Txk, and Srm, which fall outside the nine defined families. The most notable example of DSKs is the mitogen-activated protein kinase kinases (MEKs), which are principally involved in the MAP pathways.

As of now, there are over 50 FDA-approved TKIs. Comprehensive lists of FDA-approved TKIs with additional information are available at NIH PubChem and FDA.gov. Due to the broad reach of this topic and the rapid development of new drugs, this list is not fully comprehensive.

**TKI**

**Target**

**Indication**

**Deucravacitinib**

TYK2

moderate-to-severe plaque psoriasis

**Avapritinib**

PDGFR

GIST (gastrointestinal stromal tumors)

**Capmatinib**

c-MET

NSCLC (non-small cell lung cancer)

**Pemigatinib**

FGFR

Cholangiocarcinoma with FGFR2 fusions or rearrangements

**Ripretinib**

KIT/PDGFR

GIST

**Selpercatinib**

RET

NSCLC and thyroid cancer

**Selumetinib**

MEK1/2

Neurofibromatosis type 1

**Tucatinib**

Her2

HER2-positive breast cancer

**Entrectinib**

TRKA/B/C, ROS1

ROS1-positive NSCLC, Solid tumors with NTRK fusion proteins

**Erdafitinib**

FGFR

Urothelial bladder cancers

**Fedratinib**

JAK2

Myelofibrosis

**Pexidartinib**

CSF1R

Tenosynovial giant cell tumors

**Upadacitinib**

PDGFR

GIST

**Zanubrutinib**

BTK

Mantle cell lymphoma

**Baricitinib**

JAK1/2

Rheumatoid arthritis

**Binimetinib**

MEK1/2

Melanoma

**Dacomitinib**

EGFR

EGFR-mutant NSCLC

**Fostamatinib**

Syk

Chronic immune thrombocytopenia

**Gilteritinib**

Flt

Acute myelogenous leukemia (AML)

**Larotrectinib**

TRKA/B/C

Solid tumors with NTRK fusion proteins

**Lorlatinib**

ALK

ALK-positive NSCLC

**Acalabrutinib**

BTK

Mantle cell lymphoma, chronic lymphocyticÂ  leukemia (CLL), small lymphocytic lymphomas

**Brigatinib**

ALK

ALK-positive NSCLC

**Midostaurin**

Flt3

AML, advanced systemic mastocytosis, mast cell leukemia

**Neratinib**

HER2

HER2-positive breast cancer

**Alectinib**

ALK, RET

ALK-positive NSCLC

**Cobimetinib**

MEK1/2

combination therapy with vemurafenib for BRAF-positive melanoma

**Lenvatinib**

VEGFR, RET

Differentiated thyroid cancer

**Osimertinib**

EGFR

NSCLC

**Ceritinib**

ALK

ALK-positive NSCLC resistant to crizotinib

**Nintedanib**

FGFR

Idiopathic pulmonary fibrosis

**Afatinib**

EGFR, HER2, ErB4

NSCLC

**Ibrutinib**

BTK

CLL, graft vs. host disease, mantle cell lymphoma, marginal zone lymphoma

**Trametinib**

MEK1/2

Melanoma

**Axitinib**

VEGFR

Advanced renal cell carcinoma

**Bosutinib**

BCR-Abl

Chronic myelogenous leukemia (CML)

**Cabozantinib**

RET, VEGFR

Advanced medullary thyroid cancer, hepatocellular and renal cell carcinoma

**Ponatinib**

BCR-Abl

Philadelphia chromosome-positive CML or acute lymphoblastic leukemia (ALL)

**Regorafenib**

VEGFR

Colorectal cancer and hepatocellular carcinoma, GIST

**Tofacitinib**

JAK3

Rheumatoid arthritis

**Crizotinib**

ALK, ROS1

ALK or ROS1-positive NSCLC

**Ruxolitinib**

JAK1/2/3, Tyk

Myelofibrosis, polycythemia vera

**Vandetanib**

VEGFR2

Medullary thyroid cancer

**Pazopanib**

VEGFR

Renal cell carcinoma, soft tissue sarcomas

**Lapatinib**

EGFR, HER2

HER2-positive breast cancer

**Nilotinib**

BCR-Abl

Philadelphia chromosome-positive CML

**Dasatinib**

BCR-Abl

CML

**Sunitinib**

VEGFR2

GIST, pancreatic neuroendocrine tumors, renal cell carcinomas

**Sorafenib**

VEGFR

Hepatocellular carcinoma, renal cell carcinoma, differentiated thyroid cancer

**Erlotinib**

EGFR

NSCLC, pancreatic cancer

**Gefitinib**

EGFR

NSCLC

**Imatinib**

BCR-Abl, KIT, PGFR

Philadelphia chromosome-positive CML or ALL, aggressive systemic mastocytosis, chronic eosinophilic leukemia, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, GIST, myelodysplastic/myeloproliferative disease